Updates are available Erratum dated 2015-01-20

Article History

Received: 9 July 2014

Accepted: 11 September 2014

First Online: 17 October 2014

Change Date: 11 December 2014

Change Type: Corrigendum

Change Details: In the version of this paper originally published, the 'phase' entry for PBT2 in Table 1 was inadvertently labeled as 'Discontinued'. It has now been corrected to phase 2. Additionally, at the time of this corrigendum, the U.S. Food and Drug Administration status of AZD3293 has changed to phase 2/3 on Alzforum's database of amyloid-related therapeutics, and Epothilone D has been discontinued. Lastly, BIIB037 (Aducanumab) has been announced to be proceeding to phase 3 trials. The respective table entries have been amended to reflect these changes in the HTML and PDF versions of the article.

Competing interests

: The authors declare no competing financial interests.